Fischer let off hook in SEC (Securities and Exchange Commission) inquiry
This article was originally published in Clinica
The US Securities and Exchange Commission has concluded its 16-month investigation into Fischer Imaging's accounting practices. While no civil money penalties were dealt to the Denver, Colorado-based company by the Commission, Fischer agreed to entry of an order that it cease and desist from violating certain provisions of the federal securities laws.
You may also be interested in...
A Phase III trial testing the antibody-drug conjugate sacituzumab govitecan was stopped early for efficacy, boding well for the BLA pending at the US FDA.
Deal Snapshot: Six companies seek to collect convalescent plasma from COVID-19 survivors to quickly develop hyperimmune immunoglobulin therapy for serious complications of the virus.
Pharmaceutical companies struggling to keep up with coronavirus-related supply chain havoc asked to keep the US regulator informed as situation unfolds.